Hyundai Bioscience Co., Ltd. (048410.KQ)
KRW 13990.0
(-1.82%)
KRW 13990.0
(-1.82%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 14.82 Billion KRW | -51.43% |
| 2022 | 28.25 Billion KRW | 161.27% |
| 2021 | 10.81 Billion KRW | 36.25% |
| 2020 | 7.93 Billion KRW | -12.15% |
| 2019 | 9.03 Billion KRW | -26.23% |
| 2018 | 12.24 Billion KRW | -1.16% |
| 2017 | 12.39 Billion KRW | -33.1% |
| 2016 | 18.52 Billion KRW | 82.16% |
| 2015 | 10.16 Billion KRW | 7.74% |
| 2014 | 9.43 Billion KRW | -34.42% |
| 2013 | 14.39 Billion KRW | -10.97% |
| 2012 | 16.16 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.57 Billion KRW | -57.68% |
| 2024 Q2 | 3.86 Billion KRW | 150.29% |
| 2023 Q3 | 2.78 Billion KRW | -19.83% |
| 2023 Q1 | 3.73 Billion KRW | -66.75% |
| 2023 FY | 13.72 Billion KRW | -51.43% |
| 2023 Q4 | 3.72 Billion KRW | 33.77% |
| 2023 Q2 | 3.47 Billion KRW | -7.1% |
| 2022 FY | 28.25 Billion KRW | 161.27% |
| 2022 Q4 | 11.24 Billion KRW | 39.0% |
| 2022 Q1 | 3.07 Billion KRW | -28.63% |
| 2022 Q2 | 5.54 Billion KRW | 80.53% |
| 2022 Q3 | 8.09 Billion KRW | 45.86% |
| 2021 Q1 | 2.18 Billion KRW | -61.6% |
| 2021 Q4 | 4.3 Billion KRW | 54.94% |
| 2021 FY | 10.81 Billion KRW | 36.25% |
| 2021 Q2 | 1.58 Billion KRW | -27.58% |
| 2021 Q3 | 2.77 Billion KRW | 75.58% |
| 2020 Q1 | 3.96 Billion KRW | 7.58% |
| 2020 Q3 | 1.85 Billion KRW | -1.93% |
| 2020 Q4 | 5.69 Billion KRW | 206.36% |
| 2020 FY | 7.93 Billion KRW | -12.15% |
| 2020 Q2 | 1.89 Billion KRW | -52.17% |
| 2019 Q4 | 3.68 Billion KRW | 73.18% |
| 2019 Q3 | 2.12 Billion KRW | -27.37% |
| 2019 Q2 | 2.92 Billion KRW | 20.94% |
| 2019 Q1 | 2.42 Billion KRW | 1287.48% |
| 2019 FY | 9.03 Billion KRW | -26.23% |
| 2018 FY | 12.24 Billion KRW | -1.16% |
| 2018 Q3 | 2.36 Billion KRW | -33.94% |
| 2018 Q2 | 3.57 Billion KRW | 5.61% |
| 2018 Q1 | 3.38 Billion KRW | 39.94% |
| 2018 Q4 | 174.45 Million KRW | -92.62% |
| 2017 Q3 | 3.05 Billion KRW | 9.58% |
| 2017 FY | 12.39 Billion KRW | -33.1% |
| 2017 Q2 | 2.78 Billion KRW | -22.23% |
| 2017 Q1 | 3.58 Billion KRW | -54.45% |
| 2017 Q4 | 2.41 Billion KRW | -20.75% |
| 2016 Q3 | 4.12 Billion KRW | 22.23% |
| 2016 Q4 | 7.86 Billion KRW | 90.8% |
| 2016 FY | 18.52 Billion KRW | 82.16% |
| 2016 Q1 | 3.23 Billion KRW | 5.91% |
| 2016 Q2 | 3.37 Billion KRW | 4.12% |
| 2015 Q3 | 2.53 Billion KRW | 4.77% |
| 2015 Q1 | 2.72 Billion KRW | 8.9% |
| 2015 FY | 10.16 Billion KRW | 7.74% |
| 2015 Q4 | 3.05 Billion KRW | 20.6% |
| 2015 Q2 | 2.42 Billion KRW | -11.31% |
| 2014 Q3 | 2.38 Billion KRW | -2.89% |
| 2014 Q1 | 2.09 Billion KRW | -51.88% |
| 2014 FY | 9.43 Billion KRW | -34.42% |
| 2014 Q4 | 2.5 Billion KRW | 5.23% |
| 2014 Q2 | 2.45 Billion KRW | 16.94% |
| 2013 Q2 | 3.3 Billion KRW | -4.31% |
| 2013 Q4 | 4.35 Billion KRW | 33.55% |
| 2013 Q3 | 3.26 Billion KRW | -1.37% |
| 2013 FY | 14.39 Billion KRW | -10.97% |
| 2013 Q1 | 3.45 Billion KRW | -24.72% |
| 2012 Q4 | 4.59 Billion KRW | 0.0% |
| 2012 FY | 16.16 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Sam Chun Dang Pharm. Co., Ltd | 84.83 Billion KRW | 82.524% |
| ST Pharm Co.,Ltd. | 75.59 Billion KRW | 80.387% |
| ABL Bio Inc. | 65.52 Billion KRW | 77.374% |
| Cellid, Co., Ltd. | 10.97 Billion KRW | -35.085% |